Correlation of histology with biomarker status after photodynamic therapy in barrett esophagus

Cancer

Volumn 113, Issue 3, 2008, Pages 470-476

  Prasad, Ganapathy A ^a   Wang, Kenneth K ^a,c   Halling, Kevin C ^b   Buttar, Navtej S ^a   Wongkeesong, Louis Michel ^a   Zinsmeister, Alan R ^b   Brankley, Shannon M ^b   Westra, Wytske M ^a   Lutzke, Lori S ^a   Borkenhagen, Lynn S ^a   Dunagan, Kelly ^a  

^a MAYO CLINIC   (United States)

^b Mayo Clinic   (United States)

^c ST MARY S HOSPITAL   (United States)

Author keywords

Barrett esophagus; Biomarkers; Esophageal carcinoma; Photodynamic therapy; Response

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PHOTOFRIN; PROTEIN P16; PROTEIN P53; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER GRADING; CANCER RECURRENCE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOLOGY; DYSPHAGIA; DYSPLASIA; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC SURGERY; ESOPHAGOGASTRODUODENOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS CANCER; ESOPHAGUS MUCOSA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCATION; GENE LOCUS; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MCNEMAR TEST; ONCOGENE C MYC; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; PRIORITY JOURNAL;

AGED; ALGORITHMS; BARRETT ESOPHAGUS; BIOLOGICAL MARKERS; CARCINOMA; DIHEMATOPORPHYRIN ETHER; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; RECURRENCE;

EID: 49049113051     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23573     Document Type: Article

References (31)

1. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049-2053.
2. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol. 1999;94:2043-2053.
3. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol. 2000;95:1669-1676.
4. Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia [see comment]. Gastroenterology. 2001;120:1607-1619.
5. Weston AP, Sharma P, Topalovski M, Richards R, Cherian R, Dixon A. Long-term follow-up of Barrett's high-grade dysplasia. Am J Gastroenterol. 2000;95:1888-1893.
6. Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. N Engl J Med. 2003;349:2117-2127.
7. Orringer MB, Marshall B, Stirling MC. Transhiatal esophagectomy for benign and malignant disease. J Thorac Cardiovasc Surg. 1993;105:265-276,; discussion 276-277.
8. Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients [see comment]. Gastrointest Endosc. 1999;49:1-7.
9. Attwood SE, Lewis CJ, Caplin S, Hemming K, Armstrong G. Argon beam plasma coagulation as therapy for high-grade dysplasia in Barrett's esophagus [see comment]. Clin Gastroenterol Hepatol. 2003;1:258-263.
10. Kovacs BJ, Chen YK, Lewis TD, DeGuzman LJ, Thompson KS. Successful reversal of Barrett's esophagus with multipolar electrocoagulation despite inadequate acid suppression. Gastrointest Endosc. 1999;49:547-553.
11. Buttar NS, Wang KK, Lutzke LS, Krishnadath KK, Anderson MA. Combined endoscopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett's esophagus. Gastrointest Endosc. 2001;54:682-688.
12. Pacifico RJ, Wang KK, Wongkeesong LM, Buttar NS, Lutzke LS. Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus [see comment]. Clin Gastroenterol Hepatol. 2003;1:252-257.
13. Overholt BF, Lightdale CJ, Wang KK, et al. International, multicenter, partially blinded, randomized study of the efficacy of photodynamic therapy (PDT) using porfimer sodium (POR) for the ablation of high-grade dysplasia (HGD) in Barrett's esophagus (BE): results of 24-month follow up [abstract]. Gastroenterology. 2003;124(4 suppl 1):153. Abstract 151.
14. Prasad GA, Wang KK, Buttar NS, et al. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology. 2007;132:1226-1233.
15. Wong DJ, Paulson TG, Prevo LJ, et al. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res. 2001;61:8284-8289.
16. Prevo LJ, Sanchez CA, Galipeau PC, Reid BJ. p53-Mutant clones and field effects in Barrett's esophagus. Cancer Res. 1999;59:4784-4787.
17. Walch AK, Zitzelsberger HF, Bruch J, et al. Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence. Am J Pathol. 2000;156:555-566.
18. Tselepis C, Morris CD, Wakelin D, et al. Upregulation of the oncogene c-myc in Barrett's adenocarcinoma: induction of c-myc by acidified bile acid in vitro. Gut. 2003;52:174-180.
19. Garewal H, Ramsey L, Sharma P, Kraus K, Sampliner R, Fass R. Biomarker studies in reversed Barrett's esophagus. Am J Gastroenterol. 1999;94:2829-2833.
20. Dvorak K, Ramsey L, Payne CM, et al. Abnormal expression of biomarkers in incompletely ablated Barrett's esophagus. Ann Surg. 2006;244:1031-1036.
21. Hage M, Siersema PD, Vissers KJ, et al. Molecular evaluation of ablative therapy of Barrett's oesophagus. J Pathol. 2005;205:57-64.
22. Brankley SM, Wang KK, Harwood AR, et al. The development of a fluorescence in situ hybridization assay for the detection of dysplasia and adenocarcinoma in Barrett's esophagus. J Mol Diagn. 2006;8:260-267.
23. Prasad GA, Wang KK, Lutzke LS, et al. Frozen section analysis of esophageal endoscopic mucosal resection specimens in the real-time management of Barrett's esophagus. Clin Gastroenterol Hepatol. 2006;4:173-178.
24. Headrick JR, Nichols FC 3rd, Miller DL, et al. High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy. Ann Thorac Surg. 2002;73:1697-1702; discussion 1702-1703.
25. Overholt BF, Lightdale CJ, Wang KK, et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc. 2005;62:488-498.
26. Sokolova IA, Hailing KC, Jenkins RB, et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn. 2000;2:116-123.
27. Krishnadath KK, Wang KK, Taniguchi K, et al. Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy. Gastroenterology. 2000;119:624-630.
28. Hage M, Siersema PD, Vissers KJ, et al. Genomic analysis of Barrett's esophagus after ablative therapy: persistence of genetic alterations at tumor suppressor loci. Int J Cancer. 2006;118:155-160.
29. Wu TT, Watanabe T, Heitmiller R, Zahurak M, Forastiere AA, Hamilton SR. Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastric junction region. Am J Pathol. 1998;153:287-294.
30. Neshat K, Sanchez CA, Galipeau PC, et al. p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology. 1994;106:1589-1595.
31. Wongsurawat VJ, Finley JC, Galipeau PC, et al. Genetic mechanisms of TP53 loss of heterozygosity in Barrett's esophagus: implications for biomarker validation. Cancer Epidemiol Biomarkers Prev. 2006;15:509-516.